Doximity, Inc. (NASDAQ:DOCS) has received an average recommendation of 'Hold' from the twelve analysts covering the firm. One analyst has given the stock a sell rating, nine have assigned a hold rating, and two have issued a buy rating. The average one-year price target among analysts who have covered the stock in the last year is $28.30. [5d7a7f2d]
In other news, Director Kira Scherer Wampler sold 5,000 shares of Doximity stock on Tuesday, January 2nd. The shares were sold at an average price of $28.27, for a total value of $141,350. Following the sale, the director now owns 10,258 shares of the company's stock, valued at $289,993.66. The sale was disclosed in a document filed with the SEC. Company insiders own 39.40% of the company's stock.
Several hedge funds and institutional investors have recently made changes to their positions in DOCS. Geneos Wealth Management Inc. purchased a new stake in Doximity in the second quarter valued at $27,000. First Horizon Advisors Inc. increased its holdings in Doximity by 111.3% in the fourth quarter. First Horizon Advisors Inc. now owns 995 shares of the company's stock valued at $28,000 after acquiring an additional 524 shares. Quarry LP acquired a new position in Doximity in the first quarter valued at $38,000. GAMMA Investing LLC acquired a new position in Doximity in the fourth quarter valued at $40,000. Lastly, American International Group Inc. acquired a new position in Doximity in the second quarter valued at $43,000. Hedge funds and institutional investors now own 54.65% of the company's stock. [5d7a7f2d]
CG Oncology (NASDAQ:CGON) shares were down 3.9% during trading on Friday. The company traded as low as $42.39 and last traded at $42.98. Approximately 148,958 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 639,576 shares. The stock had previously closed at $44.71. A number of equities research analysts recently issued reports on CGON shares. The Goldman Sachs Group started coverage on CG Oncology in a research note on Tuesday, February 20th. They set a 'neutral' rating and a $42.00 price target for the company. HC Wainwright started coverage on CG Oncology in a research note on Wednesday, February 14th. They set a 'buy' rating and a $75.00 price target for the company. Morgan Stanley started coverage on CG Oncology in a research note on Tuesday, February 20th. They set an 'overweight' rating and a $55.00 price target for the company. Finally, Cantor Fitzgerald started coverage on CG Oncology in a report on Tuesday, February 20th. They set an 'overweight' rating and a $75.00 price objective on the stock. Insiders have bought 666,472 shares of company stock worth $12,662,968 in the last ninety days. [8b3f29e7]
Stifel downgraded ALX Oncology (ALXO) to hold, stating that it sees the company's CD47 blocker drug evorpacept as fully valued for the de-risked HER2+ gastric cancer opportunity. Stifel has a price target of $14 on the stock.
Morgens Waterfall Vintiadis & Co. Inc. has purchased a new position in DocuSign, Inc. (NASDAQ:DOCU), acquiring 72,000 shares of the company's stock valued at approximately $4,280,000. DocuSign makes up 3.2% of Morgens Waterfall Vintiadis & Co. Inc.'s portfolio, making it the 15th largest position. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Several analysts have commented on the stock, with Morgan Stanley reducing their price target on shares of DocuSign from $65.00 to $62.00 and setting an 'equal weight' rating for the company. DocuSign's stock is currently trading at $52.05, with a market capitalization of $10.69 billion. The company reported $0.15 EPS for the last quarter, beating analysts' consensus estimates of $0.09 by $0.06. Insiders have sold 47,512 shares of company stock valued at $2,746,767 in the last three months. [2e6a5c49]